The effect of the sulfated glycosaminoglycans complex on the human corneal epithelial cells proliferation: an <i>in vitro</i> experiment

Abstract

Aim to study the proliferative effect of various concentrations of sulfated glycosaminoglycans (sGAG) on the culture of human corneal epithelial cells.
 Material and methods. The study focused on the properties of a mixture of sGAG consisting of chondroitin-4-sulfate, chondroitin-6-sulfates and keratan sulfates obtained by isolation from the transparent unchanged stroma of the cornea of farm animals. The material for the in vitro study was the cells of the anterior epithelium of the human cornea.
 In the experimental group No.1, a mixture of sGAG was added to the culture medium at a concentration of 0.1%, in the experimental group No.2 at a concentration of 0.5%, in the experimental group No.3 at a concentration of 1.0%. In the control group No.1, the medium was replaced without the addition of solutions, cell seeding was carried out similarly to seeding with experimental samples. The negative control group included the holes of the tablet without the addition of medium and solution.
 Results. The highest levels of the cellular index (CI) were obtained in the experimental group No.3 (1.00% of sGAG) and amounted to 2.86 0.11 (the total increase in indicators was 60.67%). In the experimental group No.2 (0.50% sGAG), the cellular index levels were 2.650.24 (the total increase in indicators was 52.29%), which was significantly different from the experimental group No.1 (0.10% sGAG) and the control group No.1, where these indicators were 2.54 0.21 (35.81%) and 2.370.02 (25.39%) respectively.
 Conclusion. The final CI indicators show that solutions of the sGAG mixture at concentrations of 0.5% and 1.0% have a more pronounced proliferative effect on human corneal epithelial cells in vitro from the range of concentrations under study. The results obtained open up the prospects for the use of sGAG in the development of new approaches to the treatment of patients undergoing a chronic drug therapy or patients with concomitant corneal diseases.